bi 474121
Small moleculeexperimental
Clinical trial activity
6 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
6
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jan 7, 2020 (NCT04194645)
Timeline
2020s
- Jan 1, 2020
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Phosphodiesterase 2AINHIBITOR
PDE2A inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05451095 | Phase 1 | Nov 7, 2022 | Boehringer Ingelheim |
| NCT04964453 | Phase 1 | Jul 21, 2021 | Boehringer Ingelheim |
| NCT04716894 | Phase 1 | Feb 1, 2021 | Boehringer Ingelheim |
| NCT04672954 | Phase 1 | Jan 7, 2021 | Boehringer Ingelheim |
| NCT04537897 | Phase 1 | Oct 6, 2020 | Boehringer Ingelheim |
| NCT04194645 | Phase 1 | Jan 7, 2020 | Boehringer Ingelheim |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Boehringer Ingelheim | For profit | 6 | 6 | 1 | 2020 |
1 organizations
Page 1 / 1